<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9852">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01810705</url>
  </required_header>
  <id_info>
    <org_study_id>GRASPA-AML2012-01</org_study_id>
    <nct_id>NCT01810705</nct_id>
  </id_info>
  <brief_title>GRASPA Treatment for Patients With Acute Myeloblastic Leukemia</brief_title>
  <acronym>GRASPA-ML</acronym>
  <official_title>A Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients, Over 65 Years, Unfit for Intensive Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ERYtech Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ERYtech Pharma</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol aims at adding GRASPA (L-asparaginase encapsulated in red blood cells) to
      standard chemotherapy (low-dose cytarabine) to treat patients older than 65 years diagnosed
      with AML and unfit for intensive chemotherapy.

      The investigators Assume a 75% improvement in median Progression Free survival (PFS) in the
      L-asparaginase (GRASPA) plus low-dose cytarabine group compared to median PFS in the
      low-dose cytarabine group (control).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      L-asparaginase (ASNase) holds a key role in chemotherapy for Acute Lymphoblastic Leukemia
      (ALL) in children and young adults. In elderly patients, its efficacy is counterbalanced by
      its toxicity, which impairs its use. However, a current study with Red Blood Cells (RBC)
      encapsulating ASNase (GRASPA®) in elderly ALL (study reference &quot;GRASPALL-GRAAL SA2 2008&quot;)
      showed that efficacy/safety profile was positive, paving the way for introducing ASNase
      benefit into chemotherapy for elderly patients.

      In adults, Capizzi (1988) reported a significant benefit of ASNase associated with high-dose
      cytarabine treatment (HiDAC) in Acute Myeloid Leukemia (AML). Indeed, there was an overall
      statistically superior complete remission rate for HiDAC/ASNase (40%) vs HiDAC (24%) and an
      overall survival benefit for patients treated with HiDAC/ASNase (19.6 weeks vs 15.9 weeks.

      Another study in elderly patients also displayed positive results for ASNase treatment
      (Petti, 1989), as well as recent single case reports that point out the potential benefit of
      ASNase in different AML or mixed lineage leukemia (Horikoshi, 2009; Rubnitz, 2009).

      Our preclinical results also showed that an AML cell line and blast cells from the bone
      marrow of AML patients were sensitive to ASNase in vitro.

      However, up to now, the toxicity of ASNase for elderly had prevented its use in this
      population that represents the majority of AML patients.

      Aim Considering the promising results of ASNase for AML treatment and the better safety
      profile offered by RBC encapsulating ASNase (GRASPA®), a multicenter, randomized, controlled
      IIb trial is open for recruitment. Efficacy and tolerability of GRASPA® plus low-dose
      cytarabine will be evaluated versus low-dose cytarabine alone in treatment of AML patients
      over 65 year-old, unfit for intensive chemotherapy.

      One hundred and twenty-three patients (65-85 year-old) newly diagnosed for AML are planned
      for inclusion in the study.

      A 2:1 randomization will be respected (82 patients treated with GRASPA® plus low-dose
      cytarabine and 41 patients treated with low-dose cytarabine alone). Each patient will be
      followed for 24 months.

      Progression-free survival (time elapsed between treatment initiation and disease
      progression/death) will be evaluated as a primary endpoint. A 75% improvement in the median
      progression-free survival  is assumed in the experimental group vs control group.
      Percentages of remission (complete and partial), survival (event-free and overall), patient
      quality of life, general safety, pharmacodynamic/pharmacokinetic and immunogenicity of
      GRASPA® will be also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change from baseline blast count</measure>
    <time_frame>once a month, until disease progression (expected average of 8 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS): Assessment of disease (Acute myeloid leukemia) progression, recording the date the event occurs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response to treatment</measure>
    <time_frame>once a month, until the patient stop treatment (expected average of 8 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients with Complete remission, Complete remission with incomplete recovery, Partial remission (PR), stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>recording of the date of patient death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>once a month, until the patient stop treatment (expected average of 8 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>collecting survey about patients quality of life, transfusional needs, number of hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerance to treatment</measure>
    <time_frame>once a month, until the patient stop treatment (expected average of 8 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>recording of adverse events / serious adverse event and treatment causality</description>
  </secondary_outcome>
  <other_outcome>
    <measure>exploration of asparagine synthetase</measure>
    <time_frame>before treatment initiation</time_frame>
    <safety_issue>No</safety_issue>
    <description>determination of Asparagine synthetase protein expression in tumoral bone marrow cells harvested before treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>GRASPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive one injection of GRASPA (100 IU/kg) after each course of low-dose cytarabine (see Arm &quot;Control&quot;)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will receive successive courses of low intensive chemotherapy, as subcutaneous low-dose cytarabine 20mg twice daily for 10 days per course (from day 1 to day 10), each course occurring every 28 days, for a duration up to 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRASPA</intervention_name>
    <description>Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum</description>
    <arm_group_label>GRASPA</arm_group_label>
    <other_name>L-asparaginase encapsulated in red blood cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 65 years old and less than 85 years old

          -  Newly diagnosed Acute Myeloid Leukemia or post myelodysplastic syndrome diagnosed in
             the 6 months prior study enrollment

          -  Unfit for intensive chemotherapy (at risk to suffer treatment related pejorative
             toxicities /early death) or patient unwilling to receive intensive chemotherapy

          -  WHO performance status ≤2 and estimated life expectancy ≥ 3 months

          -  Eligible to receive low-dose cytarabine treatment

          -  Evidence of post-menopausal status for female (absence of menstruation for 12 months)

        Exclusion Criteria:

          -  Patients with M3 AML of French American British classification ( Acute Promyelocytic
             Leukemia)

          -  Patients with AML involving chromosome 16 abnormalities or translocation (8:21)

          -  History of grade 3-4 pancreatitis or grade 3-4 thromboembolic event

          -  Presenting with a general or visceral contraindication (Uncontrolled or severe
             cardiovascular disease ; Plasma creatinine concentration 2 times greater than the
             upper limit of laboratory ranges ; Aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) levels, 3.5 times greater than the upper limit of laboratory
             ranges ; Patient presenting evolutive cancer other than AML, except in situ
             basal-cell carcinoma or in situ cervix cancer ; Severe evolutive infection, or, HIV
             seropositive or, active hepatitis related to B or C viral infection)

          -  History of Grade 3 Transfusional incident

          -  Has known or suspected hypersensitivity or intolerance to mannitol

          -  Patient presenting contra indication to cytarabine treatment

          -  Participation in an investigational drug study within the 30 days prior to entry
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>X Thomas, Doctor</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Cecile Bonin</last_name>
    <phone>+334 78 74 44 38</phone>
    <email>cbonin@erytech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital l'Archet 1</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>F LEGRAND, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <state>Bouche du Rhone</state>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>N Vey, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital JEAN MINJOZ</name>
      <address>
        <city>Besancon</city>
        <state>Doubs</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>F Larosa, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>G Guillerm, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévèque</name>
      <address>
        <city>Pessac</city>
        <state>Gironde</state>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>T LEGUAY, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes</name>
      <address>
        <city>Nimes</city>
        <state>Guard</state>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>E Jourdan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Haut Rhin</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>P Bories, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital De Purpan CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Haute Garonne</state>
        <zip>31500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>C Recher, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Région d'Annecy</name>
      <address>
        <city>Pringy</city>
        <state>Haute Savoie</state>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>F Orsini, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Y HICHRI, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu - CHU de NANTES</name>
      <address>
        <city>Nantes</city>
        <state>Loire Atlantique</state>
        <zip>44200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>P Chevallier, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-priest-en-jarez</city>
        <state>Loire</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>E Tavernier, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu D'Angers</name>
      <address>
        <city>Angers</city>
        <state>Maine et Loire</state>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M Hunault, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <state>Meurthe et Moselle</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>C Bonmati, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude-Huriez</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>B Quesnel, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-ferrand</city>
        <state>Puy de Dome</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>R GUIEZE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hopital de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <state>Pyrénées Orientales</state>
        <zip>66100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>L Sanhes, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <state>Rhone Alpes</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>A Belhabri, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <state>Rhone Alpes</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>X Thomas, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>S Lepretre, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud</name>
      <address>
        <city>Amiens</city>
        <state>Somme</state>
        <zip>80090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>JP MAROLLEAU, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloid</keyword>
  <keyword>leukemia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
